Advanced Breast Cancer Patient T-Cell Marker Profiles

61 patient records from a study analyzing peripheral blood T-cell immunophenotypes in advanced breast cancer patients before paclitaxel chemotherapy. The dataset contains flow cytometry measurements of CD28 and PD-1 expression on T cells, correlating them with chemotherapy sensitivity and progression-free survival. It was authored by Ji Yang and last updated in April 2026.

Use Cases

• Predict progression-free survival (PFS) from CD8+CD28+ and CD3+PD-1+ expression levels.
• Classify chemotherapy sensitivity (responder vs. non-responder) using combined CD28 and PD-1 marker thresholds.
• Analyze the association between CD28 expression on T cells and immune cell infiltration in the tumor microenvironment.
• Model the effect of PD-1 blockade on cytotoxicity using in vitro PBMC and tumor cell line data referenced in the study.

Strengths

• 61 patient records with pre-treatment immunophenotype measurements.
• Explicit clinical correlations between marker expression, chemotherapy response, and progression-free survival.
• Data supports a published research hypothesis with specific biomarker findings.

Limitations

• Small sample size of 61 patients limits statistical power for generalizable models.
• Dataset scope is limited to advanced breast cancer patients undergoing a specific chemotherapy regimen.
• The 5.5 KB file size indicates a very limited set of features or aggregated summary data.

Provenance

Source

figshare, authored by Ji Yang.

Collection Method

Flow cytometry analysis of peripheral blood from 61 advanced breast cancer patients before treatment.

Time Range

Pre-treatment timepoint for the patient cohort.

Freshness

Last updated in April 2026.

Geography

null